Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IKS012
- Development stage
- Preclinical
- Lead developer
- LigaChem Biosciences, Inc.
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IKS012 is a preclinical antibody-drug conjugate (ADC) being developed for the treatment of solid tumors, designed to target folate receptor alpha (FOLR1), which is highly expressed in ovarian and other solid cancers. The molecule consists of a FOLR1-directed monoclonal antibody conjugated to a cytotoxic tubulin-inhibiting payload, enabling selective delivery of a microtubule-disrupting agent to FOLR1-positive tumor cells while sparing normal tissues. IKS012 originates from Iksuda Therapeutics’ ADC platform and is being advanced toward IND-enabling studies in collaboration with LigaChem Biosciences, with the goal of providing a more potent and tolerable option for patients with FOLR1-expressing solid tumors.[1][5][7]
- Other names
- FRα-ADC
02
Targets
FOLR1 (FRα)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on IKS012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IKS012.